CD30 transmembrane receptor, a member of the tumor necrosis factor receptor family, is expressed in different lymphomas. Brentuximab vedotin (BV), a CD30 monoclonal antibody (Ab)-drug conjugate, is effective in CD30-positive lymphomas. However, the response to BV is not always correlated to CD30 expression detected by immunohistochemistry (IHC). The objectives of this study were to standardize and evaluate CD30 intensity by flow cytometry (FCM) in non-Hodgkin's lymphomas. Twelve centers analyzed 161 cases on standardized cytometers using normalized median fluorescence intensity (nMFI30) of three different Abs, of which one clone can recognize the same epitope as BV. FCM distinguished four groups of cases: negative group (n = 110) which showed no expression with the three clones; high positive group (n = 13) which gave nMFI30 > 5% with all tested clones; dim positive group (n = 17) which showed nMFI30 > 1% with all tested clones and <5% for at least one; discordant group (n = 21) with positive and negative expression of the different clones. In consistency with the literature, CD30 was positive in all anaplastic large cell lymphomas, in some diffuse large B-cell lymphomas (DLBCL), and in other rare lymphomas. FCM results were concordant with those of IHC in 77% of cases. Discrepancies could be explained by clones-related differences, microenvironment, or intracytoplasmic staining. Interestingly, FCM was more sensitive than IHC in 11% of cases, especially in DLBCL. Multicenter standardized FCM of specific CD30 could improve case detection and extend the treatment of BV to various CD30-positive lymphomas.

中文翻译：

---

多中心 MFI30 研究：流式细胞术分析非霍奇金淋巴瘤中 CD30 表达的标准化

CD30 跨膜受体是肿瘤坏死因子受体家族的成员，在不同的淋巴瘤中表达。Brentuximab vedotin (BV) 是一种 CD30 单克隆抗体 (Ab) 药物偶联物，对 CD30 阳性淋巴瘤有效。然而，对 BV 的反应并不总是与免疫组织化学 (IHC) 检测到的 CD30 表达相关。本研究的目的是通过流式细胞术 (FCM) 在非霍奇金淋巴瘤中标准化和评估 CD30 强度。12 个中心在标准化细胞仪上使用三种不同抗体的标准化中值荧光强度 (nMFI30) 分析了 161 例病例，其中一个克隆可以识别与 BV 相同的表位。FCM区分了四组病例：阴性组（n  = 110），三个克隆均无表达；高阳性组（n  = 13)，所有测试克隆的 nMFI30 > 5%；暗阳性组 ( n  = 17)，所有测试克隆的 nMFI30 > 1%，至少一个克隆的 nMFI30 > 5%；不一致组 ( n = 21) 具有阳性和阴性表达的不同克隆。与文献一致，CD30 在所有间变性大细胞淋巴瘤、一些弥漫性大 B 细胞淋巴瘤 (DLBCL) 和其他罕见淋巴瘤中均呈阳性。在 77% 的病例中，FCM 结果与 IHC 的结果一致。差异可以通过克隆相关差异、微环境或胞质内染色来解释。有趣的是，FCM 在 11% 的病例中比 IHC 更敏感，尤其是在 DLBCL 中。特异性 CD30 的多中心标准化 FCM 可以改善病例检测并将 BV 的治疗扩展到各种 CD30 阳性淋巴瘤。